Trial · NCT07899034
Music Therapy in Post-Stroke Patients: A Clinical Trial
NCT07899034, Not applicable, Recruiting, Universidad de Granada
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Music Therapy in Post-Stroke Patients: A Clinical Trial. Trials, record NCT07899034. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899034
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Music Therapy in Post-Stroke Patients: A Clinical Trial
- NCT number
- NCT07899034
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 84 participants, estimated
- Lead sponsor
- Universidad de Granada
- Conditions
- CVA (Cerebrovascular Accident), Ictus, Stroke Acute, Insomnia, Anxiety and Depression
- Interventions
- Music therapy
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pittsburgh Sleep Quality Index (PSQI) | At study baseline and at the end of the study. | This is a validated, self-administered instrument consisting of 19 questions distributed across seven components: subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. The total score ranges from 0 to 21, with scores greater than 5 indicating poor sleep quality. The PSQI has previously been used in studies involving patients diagnosed with stroke. |
| Secondary | Insomnia Severity Index (ISI) | At study baseline and at the end of the study. | This validated scale allows the assessment of insomnia severity and its functional impact. It consists of 7 items assessing difficulties in falling sleep and maintaining sleep, satisfaction with sleep, the impact on daily activities, and the degree of concern associated with sleep difficulties. Each item is scored on a scale from 0 to 4, with a total score ranging from 0 to 28. Based on the total score, the following severity levels are established: * From 0 to 7: absence of clincally significant insomnia. * From 8 to 14: subclinical insomnia. * From 15 to 21: moderate insomnia. * From 22 to 28: severe insomnia. |
| Secondary | Hospital Anxiety and Depression Scale (HADS) | At study baseline and at the end of the study. | This scale consist of 14 items, organized in two subscales: * Anxiety subscale (HADS-A): identifies symptoms associated with anxiety. * Depression subscale (HADS-D): assesses symptoms associated with depression. Each item is scored on a scale from 0 to 3 points, where 0 represents the absence of symptoms and 3 represents the greatest symptom severity. Thus, each subescale can achieve a total score ranging from 0 to 21 points. * From 0 to 7: normal emotional state. * From 8 to 10: mild anxiety or depression. * From 11 to 14: moderate anxiety or depression. * From 15 to 21: severe anxiety or depression. |
| Secondary | Glasgow Coma Scale (GCS) | At study baseline | This scale is used to measure the level of consciousness and brain injury. It consists of three components: * Eye opening: scored on a scale of 1 to 4 points, where 1 corresponds to no eye opening anda 4 to spontaneous eye opening. * Verbal response: scored from 1 to 5, with 1 indicating no verbal response and 5 indicatin an oriented and appropiate response. * Motor response: scored from 1 to 6, where 1 indicates no motor response and 6 indicates the ability to follow commands. The sum of the three components yields a total score ranging from 3 to 15 points. Scores of 8 or lower indicate a severe coma and require immediate intervention. |
| Secondary | Canadian Neurological Scale (CNS) | At study baseline | Neurological status in patients with stroke is assessed using this scale. It is structured into three domains, although only two of them were analyzed in this study: * Mental function: * Level of consciousness: distinguishing between alert and drowsy patients, as well as assessing their level of orientation in time and space. * Language: assessed as normal, with impaired expression, or with impaired comprehension. * Motor functions: * Patients without comprehension impairment: facial function and motor function in the upper limb (proximal and distal) and lower limbs are assessed. * Patients with comprehension impairment: the same motor areas are assessed, with evaluations performed periodically accordign to established protocols, generally every four hours. |
| Secondary | Patient satisfaction scale | Immediately after the intervention | It consists of a five-item questionnaire assessing the perceived benefits of music therapy, the feeling of relaxation experienced during the sessions, the suitability of the setting in which the intervention was delivered, the appropriateness of the number and duration of the sessions, and whether participants wpuld recommend this intervention. |
| Secondary | Sociodemographic data and clinical variables | Baseline, pre-intervention | An ad hoc instrument is administered to collect sociodemographic data (age and sex). Clinical variables are obtained from the electronic medical record available throug the Diraya system |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers29
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899034
GET https://conductscience.org/api/trials/v1/NCT07899034/papers?page=2